mesna and Esophageal-Neoplasms

mesna has been researched along with Esophageal-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for mesna and Esophageal-Neoplasms

ArticleYear
A feasibility study of chemically assisted endoscopic submucosal mechanical dissection using mesna for superficial esophageal squamous cell carcinomas.
    Surgical endoscopy, 2015, Volume: 29, Issue:11

    Injection of mesna into submucosal layers was recently reported to chemically soften connective tissue and facilitate the gastric endoscopic submucosal dissection (ESD) procedure. This study aimed to evaluate the safety and feasibility of similarly using mesna for esophageal ESD (mesna ESD).. We performed mesna ESD in 20 consecutive patients with superficial esophageal squamous cell carcinomas (SESCCs). To do this, a submucosal fluid cushion was initially formed using sodium hyaluronate, and the esophageal lesion was circumferentially isolated with a short blade needle-knife. Mesna solution was then injected into the submucosal layer, which was dissected mechanically by cleavage using the tip of a cap-fitted endoscope. The number of electrosurgical incisions was recorded by computer software in real time. The data from 20 conventional ESD procedures without mesna (consecutive 10 SESCCs pre and post the 20 consecutive mesna ESD) were used for comparison to evaluate the mesna ESD.. The mesna ESDs achieved en bloc and R0 resection success rates of 100 and 95 %, respectively. There was no perforation or uncontrollable hemorrhage during and after mesna ESD, and the median procedural time of submucosal dissection was significantly less with mesna ESD than with conventional ESD (median; 8 vs. 15 min, P < 0.05). There were also significantly fewer electrosurgical incisions made during the mesna ESD than with conventional ESDs (median; 65 vs. 183 times, P < 0.01).. Mesna ESD for SESCCs is a safe procedure with the potential to facilitate esophageal ESD.

    Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Dissection; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagoscopy; Esophagus; Expectorants; Feasibility Studies; Female; Humans; Injections; Male; Mesna; Middle Aged; Mucous Membrane; Prospective Studies; Treatment Outcome

2015
Ifosfamide in advanced carcinoma of the esophagus: a phase II trial with severe toxicity.
    American journal of clinical oncology, 1989, Volume: 12, Issue:3

    Seventeen patients with advanced epidermoid carcinoma of the esophagus were treated with ifosfamide (IFOS) 1.5 mg/m2/day intravenously on days 1-5 every 28 days. Mesna was given concurrently at 20% of the IFOS dose prior to and 4 and 8 h after IFOS for uroprotection. Toxicity in this trial was severe since life-threatening leukopenia occurred in one patient, Grade 3 nausea and vomiting (necessitating termination of treatment) in two patients, and Grade 3 neurotoxicity (cerebellar dysfunction) in two patients. Two patients developed severe infections (Grade 3). Only four patients experienced no toxicity. One patient had a partial response with a response duration of 8 weeks. The median survival of all patients is 10 weeks. It is concluded that IFOS as given in this trial has limited activity in esophagus carcinoma with severe toxicity.

    Topics: Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Evaluation; Esophageal Neoplasms; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged

1989